Concepedia

Morvarid Mohseni

MM

Statistics

Publications

24

Citations

4.2K

H-Index

21

Active since

2008

Affiliations

Novartis (Switzerland)(Current)

Harvard University

Novartis (United States)

Boston Children's Hospital

Harvard Stem Cell Institute

Morvarid Mohseni is an author at Novartis (Switzerland) specializing in molecular oncology, oncology, and medicine.

Publications per year

2008–2023

24

Publications

24

Yap1 Acts Downstream of α-Catenin to Control Epidermal Proliferation

Karin Schlegelmilch, Morvarid Mohseni, Oktay Kirak et al. · Cell · 2011 · 1.1K citations · Full text

Life Sciences, Cell Biology, Molecular Biology +13

AZD9150, a next-generation antisense oligonucleotide inhibitor of <i>STAT3</i> with early evidence of clinical activity in lymphoma and lung cancer

David S. Hong, Razelle Kurzrock, Youngsoo Kim et al. · Science Translational Medicine · 2015 · 440 citations · Full text

Medicine, Cancer Biology, Oncology +8

Inhibition of Inflammatory Signaling in Tet2 Mutant Preleukemic Cells Mitigates Stress-Induced Abnormalities and Clonal Hematopoiesis

Zhigang Cai, Jonathan J. Kotzin, Baskar Ramdas et al. · Cell stem cell · 2018 · 390 citations · Full text

Life Sciences, Cell Biology, Hematology +10

Hippo Signaling Regulates Microprocessor and Links Cell-Density-Dependent miRNA Biogenesis to Cancer

Masaki Mori, Robinson Triboulet, Morvarid Mohseni et al. · Cell · 2014 · 342 citations · Full text

Medicine, Molecular Biology, Oncology +14

A genetic screen identifies an LKB1–MARK signalling axis controlling the Hippo–YAP pathway

Morvarid Mohseni, Jianlong Sun, Allison N. Lau et al. · Nature Cell Biology · 2013 · 294 citations · Full text

Life Sciences, Genetics, Molecular Genetics +10

1–5 of 24